Hemant Surgical Partners GBT Korea for Advanced C-ARM Imaging

INDUSTRIAL-GOODSSERVICES
Whalesbook Corporate News Logo
AuthorAnanya Iyer|Published at:
Hemant Surgical Partners GBT Korea for Advanced C-ARM Imaging
Overview

Hemant Surgical Industries has entered a key C-ARM Development and Supply Agreement with South Korea's GBT Korea Co., Ltd. This collaboration focuses on developing and localizing advanced x-ray generators and C-ARM imaging devices. The partnership leverages GBT Korea's technological expertise, signaling Hemant Surgical's strategic intent to move into higher-value, sophisticated medical equipment manufacturing.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Hemant Surgical Industries Ltd., which reported FY25 revenue of ₹75.20 crore and a profit of ₹3.60 crore, has signed a strategic C-ARM Development and Supply Agreement with South Korea's GBT Korea Co., Ltd.

Strategic Deal for Advanced Medical Imaging

The agreement with GBT Korea, a company based in South Korea, centers on the development and localization of advanced x-ray generators and C-ARM imaging devices.

This partnership will leverage GBT Korea's extensive technological expertise in X-ray imaging systems. The focus is on advanced C-ARM devices for critical applications including surgical, orthopaedic, trauma, and cardio-vascular procedures, signaling a significant strategic step for Hemant Surgical.

Details regarding the financial terms of this developmental and supply agreement have not been disclosed by either company.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.